What is behind programmatic treatment outcome definitions for tuberculosis?
- 23 July 2020
- journal article
- editorial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (1), 2001751
- https://doi.org/10.1183/13993003.01751-2020
Abstract
Rationale for programmatic TB definitions in management of TB and MDR-TB https://bit.ly/36BYD2EThis publication has 8 references indexed in Scilit:
- Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant TuberculosisEmerging Infectious Diseases, 2020
- Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectivesEuropean Respiratory Review, 2019
- Failing treatment of multidrug-resistant tuberculosis: a matter of definitionThe International Journal of Tuberculosis and Lung Disease, 2019
- Evolution of Programmatic Definitions Used in Tuberculosis Prevention and CareClinical Infectious Diseases, 2018
- Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not CureAmerican Journal of Respiratory and Critical Care Medicine, 2017
- History of Tuberculosis and Drug ResistanceThe New England Journal of Medicine, 2013
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patientsEuropean Respiratory Journal, 1998